ArticleBMC cancer2025
Radical surgery versus definitive radiotherapy in treatment of locoregional upper esophageal squamous cell carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neoadjuvant versus adjuvant chemoradiotherapy for resectable cT3-4a esophageal squamous cell carcinoma: A matched cohort analysis.Precision radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundsCurrent consensus guidelines lack robust evidence to advocate the optimal treatment approach for locoregional upper esophageal squamous cell carcinoma (L-UESCC). The purpose of this study was to conduct an in-depth investigation of the treatment patterns, outcomes, and prognostic factors among patients with L-UESCC.
methodsConsecutive patients diagnosed with L-UESCC who underwent curative-intent treatment at two cancer centers from January 2013 to December 2018 were enrolled in this study. To compare overall survival (OS) and conduct prognostic analysis, we employed the Kaplan-Meier method, Cox regression models, and propensity score matching (PSM).
resultsIn the entire cohort, 247 patients (64.2%) received definitive radiotherapy, whereas 138 patients (35.8%) underwent radical surgery. Multivariable Cox analysis revealed that T stage, N stage, and tumor length were independent predictors of OS. The Kaplan-Meier analysis demonstrated comparable median OS between the surgical and radiotherapy groups both before and after PSM adjustment. Before PSM, the median OS was 27.0 months in the surgical group and 29.0 months in the radiotherapy group (P = 0.48); after PSM, it was 23.0 and 30.0 months respectively (P = 0.38). Notably, the combination of chemotherapy with radiotherapy was associated with a significant survival benefit over radiotherapy monotherapy (median OS 36.0 versus 20.0 months, P = 0.005). In chemotherapy-naïve subgroups, surgery conferred a significant survival advantage over radiotherapy (P = 0.016), particularly in stage I-II (P = 0.003), but not in stage III (P = 0.54).
conclusionsIn patients with L-UESCC, surgical resection and definitive radiotherapy yielded similar OS results. Formulating personalized treatment strategies requires a multidisciplinary approach integrating systemic and local therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.